Group
IDH inhibitor
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | IDH inhibitors |
| Mechanism of Action | IDH1 inhibitor |
| Drugs in group | Ivosidenib· Vorasidenib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Conflicting/unresolved—inhibitors may be radioprotective (restoring redox/DDR) or radiosensitizing (suppressing HR) (Molenaar et al., Oncogene, 2018; Rudà et al., Nature Reviews Neurology, 2024). Given this uncertainty, the side-effect direction is likewise unclear; if radioprotective, no added normal-tissue side-effects would be expected.
The data above refer to patients treated with IDH inhibitor as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.